Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 350 Polycystic Ovary Syndrome 39 Endometrial Neoplasms 22 Neoplasm Metastasis 21 Ovarian Neoplasms 16 Infertility 12 Neoplasms 11 Fallopian Tube Neoplasms 8 Advanced Breast Cancer 8 Triple Negative Breast Neoplasms 7 Carcinoma, Intraductal, Noninfiltrating 7 Carcinoma, Ductal, Breast 7 Breast Neoplasms, Male 7 Recurrence 6 Osteoporosis 6 Carcinoma, Lobular 6 Breast Diseases 6 Breast Carcinoma In Situ 6 Prostatic Neoplasms 5 Leiomyoma 4 Infertility, Female 4 Hereditary Sensory and Autonomic Neuropathies 4 Breast Cancer Metastatic 4 Neoplasms, Hormone-Dependent 3 Carcinoma, Ovarian Epithelial 3 Carcinoma, Non-Small-Cell Lung 3 Anovulation 3 Uterine Neoplasms 2 Uterine Cervical Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 2

Interventions

Sirolimus 9 Everolimus 5 Imatinib Mesylate 2 temsirolimus 1 saracatinib 1 nintedanib 1 carbon-11 acetate 1 Valproic Acid 1 Sugars 1 Simvastatin 1 Resveratrol 1 Octreotide 1 Loratadine 1 Letrozole 1 Immunoglobulin G 1 Hydroxychloroquine 1 Glutamine 1 Doxycycline 1 Disulfides 1 Cetuximab 1 Celecoxib 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Lymphangioleiomyomatosis × Letrozole × Clear all

NCT01353209 2024-04-17

TRAIL

University of Cincinnati

Phase 2 Completed

17 enrolled 13 charts

Lymphangioleiomyomatosis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡